Summary

An investigational anti-interferon-a monoclonal antibody, sifalimumab, reduced global disease activity in patients with systemic lupus erythematosus (SLE). This article presents results from a phase 2b study of sifalimumab in patients with moderate to severe SLE.

  • Rheumatology Clinical Trials
  • Lupus
  • Rheumatology Clinical Trials
  • Rheumatology
  • Lupus
View Full Text